Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Review

USP4 function and multifaceted roles in cancer: a possible and potential therapeutic target

Authors: Yizhi Wang, Li Zhou, Jun Lu, Bolun Jiang, Chengxi Liu, Junchao Guo

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Cancer remains one of the major culprits causing disease-related deaths and leads to a high morbidity and similar mortality. Insidious onset, difficult early detection and a lack of broad-spectrum and effective multi-cancer therapeutic targets have limited the prolongation of cancer patients’ survival for decades. Therefore, a versatile therapeutic target which is involved in various cancer-related signaling pathways and different cancers may be more effective for cancer targeted therapy. USP4, one of the DUBs members which participates in deubiquitination, an inverse process of ubiquitination, can regulate various classical cancer-related signaling pathways, and thereby plays a vital role in some pathological and physiological processes including tumor initiation and progression. Recently, USP4 has been found to exert versatile influences on cells proliferation, migration and invasion, also apoptosis of various tumors. Moreover, USP4 can also act as a prognostic biomarker in several cancers. This review will give a comprehensive introduction of USP4 about its regulatory mechanisms, related signaling pathways, pathophysiological functions and the roles in various cancers which may help us better understand its biological functions and improve future studies to construct suitable USP4-targeted cancer therapy system.
Literature
1.
2.
Smith GL, Lopez-Olivo MA, Advani PG, Ning MS, Geng Y, Giordano SH, et al. Financial burdens of cancer treatment: a systematic review of risk factors and outcomes. J Natl Compr Cancer Netw. 2019;17(10):1184–92.CrossRef
3.
May P, Normand C, Morrison RS. Economics of palliative care for cancer: interpreting current evidence, mapping future priorities for research. J Clin Oncol. 2020;38(9):980–6.PubMedCrossRef
4.
Maeda S, Unno M, Yu J. Adjuvant and neoadjuvant therapy for pancreatic cancer. J Pancreatol. 2019;2:100–6.CrossRef
5.
Wu WM, Jin G, Wang CY, Miao Y, Wang HZ, Lou WH, Pancreatic Surgery Study Group of Chinese Society of Surgery of Chinese Medical Association, et al. The current surgical treatment of pancreatic cancer in China: a national wide cross-sectional study. J Pancreatol. 2019;2:16–21.CrossRef
6.
Dezube AR, Jaklitsch MT. New evidence supporting lung cancer screening with low dose CT & surgical implications. Eur J Surg Oncol. 2020;46(6):982–90.PubMedCrossRef
7.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2020;69(1):7–34.CrossRef
8.
Liang J, Shi J, Wang N, Zhao H, Sun J. Tuning the protein phosphorylation by receptor type protein tyrosine phosphatase epsilon (PTPRE) in normal and cancer cells. J Cancer. 2019;10(1):105–11.PubMedPubMedCentralCrossRef
9.
Balasubramaniyan N, Luo Y, Sun AQ, Suchy FJ. SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes. J Biol Chem. 2013;288(19):13850–62.PubMedPubMedCentralCrossRef
10.
Busold S, Nagy NA, Tas SW, van Ree R, de Jong EC, Geijtenbeek TBH. Various tastes of sugar: the potential of glycosylation in targeting and modulating human immunity via C-type lectin receptors. Front Immunol. 2020;11:134.PubMedPubMedCentralCrossRef
11.
12.
13.
Chen B, Sun Y, Niu J, Jarugumilli GK, Wu X. Protein lipidation in cell signaling and diseases: function, regulation, and therapeutic opportunities. Cell Chem Biol. 2018;25(7):817–31.PubMedPubMedCentralCrossRef
14.
Brentville VA, Vankemmelbeke M, Metheringham RL, Durrant LG. Post-translational modifications such as citrullination are excellent targets for cancer therapy. Semin Immunol. 2020;47:101393.PubMedCrossRef
15.
16.
17.
Li X, Elmira E, Rohondia S, Wang J, Liu J, Dou QP. A patent review of the ubiquitin ligase system: 2015–2018. Expert Opin Ther Pat. 2018;28(12):919–37.PubMedPubMedCentralCrossRef
18.
19.
Veggiani G, Gerpe MCR, Sidhu SS, Zhang W. Emerging drug development technologies targeting ubiquitination for cancer therapeutics. Pharmacol Ther. 2019;199:139–54.PubMedPubMedCentralCrossRef
20.
Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, et al. A genomic and functional inventory of deubiquitinating enzymes. Cell. 2005;123(5):773–86.PubMedCrossRef
21.
22.
Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002;82(2):373–428.PubMedCrossRef
23.
24.
Altun M, Kramer HB, Willems LI, McDermott JL, Leach CA, Goldenberg SJ, et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem Biol. 2011;18(11):1401–12.PubMedCrossRef
25.
Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 2010;70(22):9265–76.PubMedCrossRef
26.
Sacco JJ, Coulson JM, Clague MJ. Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life. 2010;62(2):140–57.PubMedPubMedCentral
27.
Soboleva TA, Jans DA, Johnson-Saliba M, Baker RT. Nuclear-cytoplasmic shuttling of the oncogenic mouse UNP/USP4 deubiquitylating enzyme. J Biol Chem. 2005;280(1):745–52.PubMedCrossRef
28.
Zhang L, Zhou F, Drabsch Y, Gao R, Snaar-Jagalska BE, Mickanin C, et al. USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nat Cell Biol. 2012;14(7):717–26.PubMedCrossRef
29.
Deng L, Chen L, Zhao L, Xu Y, Peng X, Wang X, et al. Ubiquitination of Rheb governs growth factor-induced mTORC1 activation. Cell Res. 2019;29(2):136–50.PubMedCrossRef
30.
Das T, Kim EE, Song EJ. Phosphorylation of USP15 and USP4 regulates localization and spliceosomal deubiquitination. J Mol Biol. 2019;431(19):3900–12.PubMedCrossRef
31.
Kwon SK, Kim EH, Baek KH. RNPS1 is modulated by ubiquitin-specific protease 4. FEBS Lett. 2017;591(2):369–81.PubMedCrossRef
32.
Uras IZ, List T, Nijman SM. Ubiquitin-specific protease 4 inhibits mono-ubiquitination of the master growth factor signaling kinase PDK1. PLoS ONE. 2012;7(2):e31003.PubMedPubMedCentralCrossRef
33.
Zhao B, Velasco K, Sompallae R, Pfirrmann T, Masucci MG, Lindsten K. The ubiquitin specific protease-4 (USP4) interacts with the S9/Rpn6 subunit of the proteasome. Biochem Biophys Res Commun. 2012;427(3):490–6.PubMedCrossRef
34.
35.
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509–12.PubMedCrossRef
36.
Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398(6726):422–6.PubMedCrossRef
37.
Zhao B, Schlesiger C, Masucci MG, Lindsten K. The ubiquitin specific protease 4 (USP4) is a new player in the Wnt signalling pathway. J Cell Mol Med. 2009;13(8B):1886–95.PubMedCrossRef
38.
Yun SI, Kim HH, Yoon JH, Park WS, Hahn MJ, Kim HC, et al. Ubiquitin specific protease 4 positively regulates the WNT/β-catenin signaling in colorectal cancer. Mol Oncol. 2015;9(9):1834–51.PubMedPubMedCentralCrossRef
39.
Zhang J, Zhang X, Xie F, Zhang Z, van Dam H, Zhang L, et al. The regulation of TGF-β/SMAD signaling by protein deubiquitination. Protein Cell. 2014;5(7):503–17.PubMedPubMedCentralCrossRef
40.
Zhou F, Xie F, Jin K, Zhang Z, Clerici M, Gao R, et al. USP4 inhibits SMAD4 monoubiquitination and promotes activin and BMP signaling. EMBO J. 2017;36(11):1623–39.PubMedPubMedCentralCrossRef
41.
Fan YH, Yu Y, Mao RF, Tan XJ, Xu GF, Zhang H, et al. USP4 targets TAK1 to downregulate TNFα-induced NF-κB activation. Cell Death Differ. 2011;18(10):1547–60.PubMedPubMedCentralCrossRef
42.
Liang L, Fan Y, Cheng J, Cheng D, Zhao Y, Cao B, et al. TAK1 ubiquitination regulates doxorubicin-induced NF-κB activation. Cell Signal. 2013;25(1):247–54.PubMedCrossRef
43.
Xiao N, Li H, Luo J, Wang R, Chen H, Chen J, et al. Ubiquitin-specific protease 4 (USP4) targets TRAF2 and TRAF6 for deubiquitination and inhibits TNFα-induced cancer cell migration. Biochem J. 2012;441(3):979–86.PubMedCrossRef
44.
Li Z, Hao Q, Luo J, Xiong J, Zhang S, Wang T, et al. USP4 inhibits p53 and NF-κB through deubiquitinating and stabilizing HDAC2. Oncogene. 2016;35(22):2902–12.PubMedCrossRef
45.
Zhou L, Jiang H, Du J, Li L, Li R, Lu J, et al. USP15 inhibits multiple myeloma cell apoptosis through activating a feedback loop with the transcription factor NF-κBp65. Exp Mol Med. 2018;50(11):151.PubMedCentralCrossRef
46.
Chen Y, Xin H, Peng H, Shi Q, Li M, Yu J, et al. Hypomethylation-linked activation of PLCE1 impedes autophagy and promotes tumorigenesis through MDM2-mediated ubiquitination and destabilization of p53. Cancer Res. 2020;80(11):2175–89.PubMedCrossRef
47.
48.
Fu R, Yang P, Sajid A, Li Z. Avenanthramide A induces cellular senescence via miR-129-3p/Pirh2/p53 signaling pathway to suppress colon cancer growth. J Agric Food Chem. 2019;67(17):4808–16.PubMedCrossRef
49.
50.
51.
Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol. 2012;56(5):1171–80.CrossRefPubMed
52.
Zhu J, Luo Z, Pan Y, Zheng W, Li W, Zhang Z, et al. H19/miR-148a/USP4 axis facilitates liver fibrosis by enhancing TGF-β signaling in both hepatic stellate cells and hepatocytes. J Cell Physiol. 2019;234(6):9698–710.PubMedCrossRef
53.
Wu HM, Kim TH, Kim A, Koo JH, Joo MS, Kim SG. Liver X receptor α-induced cannabinoid receptor 2 inhibits ubiquitin-specific peptidase 4 through miR-27b, protecting hepatocytes from TGF-β. Hepatol Commun. 2019;3(10):1373–87.PubMedPubMedCentralCrossRef
54.
Zhao Y, Gao L, Xu L, Tong R, Lin N, Su Y, et al. Ubiquitin-specific protease 4 is an endogenous negative regulator of metabolic dysfunctions in nonalcoholic fatty liver disease. Hepatology. 2018;68(3):897–917.PubMedCrossRef
55.
Zhou J, Qiu T, Wang T, Chen Z, Ma X, Zhang L, et al. USP4 deficiency exacerbates hepatic ischaemia/reperfusion injury via TAK1 signalling. Clin Sci. 2019;133(2):335–49.CrossRef
56.
57.
Zhou F, Zhang X, van Dam H, Ten Dijke P, Huang H, Zhang L. Ubiquitin-specific protease 4 mitigates Toll-like/interleukin-1 receptor signaling and regulates innate immune activation. J Biol Chem. 2012;287(14):11002–10.PubMedPubMedCentralCrossRef
58.
Yang J, Xu P, Han L, Guo Z, Wang X, Chen Z, et al. Cutting edge: ubiquitin-specific protease 4 promotes Th17 cell function under inflammation by deubiquitinating and stabilizing RORγt. J Immunol. 2015;194(9):4094–7.PubMedCrossRef
59.
Lee W, Kim HS, Baek SY, Lee GR. Transcription factor IRF8 controls Th1-like regulatory T-cell function. Cell Mol Immunol. 2016;13(6):785–94.PubMedCrossRef
60.
61.
Lin R, Nie J, Ren J, Liang R, Li D, Wang P, et al. USP4 interacts and positively regulates IRF8 function via K48-linked deubiquitination in regulatory T cells. FEBS Lett. 2017;591(12):1677–86.PubMedCrossRef
62.
Guo Z, Xu P, Ge S, Zhang C, Zheng X, Xu J, et al. Ubiquitin specific peptidase 4 stabilizes interferon regulatory factor protein and promotes its function to facilitate interleukin-4 expression in T helper type 2 cells. Int J Mol Med. 2017;40(4):979–86.PubMedPubMedCentralCrossRef
63.
Liu C, Liu C, Liu H, Gong L, Tao T, Shen Y, et al. Increased expression of ubiquitin-specific protease 4 participates in neuronal apoptosis after intracerebral hemorrhage in adult rats. Cell Mol Neurobiol. 2017;37(3):427–35.PubMedCrossRef
64.
Jiang X, Yu M, Ou Y, Cao Y, Yao Y, Cai P, et al. Downregulation of USP4 promotes activation of microglia and subsequent neuronal inflammation in rat spinal cord after injury. Neurochem Res. 2017;42(11):3245–53.PubMedCrossRef
65.
Zhang L, Zhao X, Zhang M, Zhao W, Gao C. Ubiquitin-specific protease 2b negatively regulates IFN-β production and antiviral activity by targeting TANK-binding kinase 1. J Immunol. 2014;193(5):2230–7.PubMedCrossRef
66.
Pauli EK, Chan YK, Davis ME, Gableske S, Wang MK, Feister KF, et al. The ubiquitin-specific protease USP15 promotes RIG-I-mediated antiviral signaling by deubiquitylating TRIM25. Sci Signal. 2014;7(307):ra3.PubMedPubMedCentralCrossRef
67.
68.
Oshiumi H, Matsumoto M, Hatakeyama S, Seya T. Riplet/RNF135, a RING finger protein, ubiquitinates RIG-I to promote interferon-beta induction during the early phase of viral infection. J Biol Chem. 2009;284(2):807–17.PubMedCrossRef
69.
Cui J, Song Y, Li Y, Zhu Q, Tan P, Qin Y, et al. USP3 inhibits type I interferon signaling by dubiquitinating RIG-I-like receptors. Cell Res. 2014;24(4):400–16.PubMedCrossRef
70.
Chen R, Zhang L, Zhong B, Tan B, Liu Y, Shu HB. The ubiquitin-specific protease 17 is involved in virus-triggered type I IFN signaling. Cell Res. 2010;20(7):802–11.PubMedCrossRef
71.
Wang L, Zhao W, Zhang M, Wang P, Zhao K, Zhao X, et al. USP4 positively regulates RIG-I-mediated antiviral response through deubiquitination and stabilization of RIG-I. J Virol. 2013;87(8):4507–15.PubMedPubMedCentralCrossRef
72.
Xu C, Peng Y, Zhang Q, Xu XP, Kong XM, Shi WF. USP4 positively regulates RLR-induced NF-κB activation by targeting TRAF6 for K48-linked deubiquitination and inhibits enterovirus 71 replication. Sci Rep. 2018;8(1):13418.PubMedPubMedCentralCrossRef
73.
Liu H, Zhang H, Wang X, Tian Q, Hu Z, Peng C, et al. The deubiquitylating enzyme USP4 cooperates with CtIP in DNA double-strand break end resection. Cell Rep. 2015;13(1):93–107.PubMedCrossRef
74.
Wijnhoven P, Konietzny R, Blackford AN, Travers J, Kessler BM, Nishi R, et al. USP4 auto-deubiquitylation promotes homologous recombination. Mol Cell. 2015;60(3):362–73.PubMedPubMedCentralCrossRef
75.
Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107(4):513–23.PubMedCrossRef
76.
Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513–21.PubMedCrossRef
77.
Liu B, Wu S, Han L, Zhang C. β-catenin signaling induces the osteoblastogenic differentiation of human pre-osteoblastic and bone marrow stromal cells mainly through the upregulation of osterix expression. Int J Mol Med. 2015;36(6):1572–82.PubMedPubMedCentralCrossRef
78.
Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem. 2005;280(39):33132–40.PubMedCrossRef
79.
Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8(5):751–64.PubMedCrossRef
80.
Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010;30(12):3071–85.PubMedPubMedCentralCrossRef
81.
Zhou F, Li F, Fang P, Dai T, Yang B, van Dam H, et al. Ubiquitin-specific protease 4 antagonizes osteoblast differentiation through dishevelled. J Bone Miner Res. 2016;31(10):1888–98.PubMedCrossRef
82.
Rudnicki MA, Jaenisch R. The MyoD family of transcription factors and skeletal myogenesis. BioEssays. 1995;17(3):203–9.PubMedCrossRef
83.
Yun SI, Kim KK. Ubiquitin-specific protease 4 (USP4) suppresses myoblast differentiation by down regulating MyoD activity in a catalytic-independent manner. Cell Signal. 2017;35:48–60.PubMedCrossRef
84.
He B, Zhao YC, Gao LC, Ying XY, Xu LW, Su YY, et al. Ubiquitin-specific protease 4 is an endogenous negative regulator of pathological cardiac hypertrophy. Hypertension. 2016;67(6):1237–48.PubMedCrossRef
85.
Okamoto I. Combination therapy with molecularly targeted agents in lung cancer. Ann Oncol. 2017;28(Suppl 9):ix5.CrossRef
86.
Zhong M, Jiang Q, Jin R. USP4 expression independently predicts favorable survival in lung adenocarcinoma. IUBMB Life. 2018;70(7):670–7.PubMedCrossRef
87.
Okuda H, Kobayashi A, Xia B, Watabe M, Pai SK, Hirota S, et al. Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res. 2012;72(2):537–47.PubMedCrossRef
88.
Bernert B, Porsch H, Heldin P. Hyaluronan synthase 2 (HAS2) promotes breast cancer cell invasion by suppression of tissue metalloproteinase inhibitor 1 (TIMP-1). J Biol Chem. 2011;286(49):42349–59.PubMedPubMedCentralCrossRef
89.
Mehić M, de Sa VK, Hebestreit S, Heldin CH, Heldin P. The deubiquitinating enzymes USP4 and USP17 target hyaluronan synthase 2 and differentially affect its function. Oncogenesis. 2017;6(6):e348.PubMedPubMedCentralCrossRef
90.
Lai CY, Yeh DW, Lu CH, Liu YL, Chuang YC, Ruan JW, et al. Epigenetic silencing of ubiquitin specific protease 4 by snail1 contributes to macrophage-dependent inflammation and therapeutic resistance in lung cancer. Cancers. 2020;12(1):148.PubMedCentralCrossRef
91.
Hwang SJ, Lee HW, Kim HR, Lee H, Shin CH, Yun SI, et al. Ubiquitin-specific protease 4 controls metastatic potential through β-catenin stabilization in brain metastatic lung adenocarcinoma. Sci Rep. 2016;6:21596.PubMedPubMedCentralCrossRef
92.
Cao WH, Liu XP, Meng SL, Gao YW, Wang Y, Ma ZL, et al. USP4 promotes invasion of breast cancer cells via Relaxin/TGF-β1/Smad2/MMP-9 signal. Eur Rev Med Pharmacol Sci. 2016;20(6):1115–22.PubMed
93.
Wang Y, Zhang J, Wu L, Liu W, Wei G, Gong X, et al. Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth. Breast Cancer Res. 2018;20(1):83.PubMedPubMedCentralCrossRef
94.
Geng N, Li Y, Zhang W, Wang F, Wang X, Jin Z, et al. A PAK5-DNPEP-USP4 axis dictates breast cancer growth and metastasis. Int J Cancer. 2020;146(4):1139–51.PubMedCrossRef
95.
Li Y, Jiang D, Zhang Q, Liu X, Cai Z. Ubiquitin-specific protease 4 inhibits breast cancer cell growth through the upregulation of PDCD4. Int J Mol Med. 2016;38(3):803–11.PubMedPubMedCentralCrossRef
96.
Zhang L, Xing M, Wang X, Cao W, Wang H. MiR-148a suppresses invasion and induces apoptosis of breast cancer cells by regulating USP4 and BIM expression. Int J Clin Exp Pathol. 2017;10(8):8361–8.PubMedPubMedCentral
97.
Liang Y, Song X, Li Y, Ma T, Su P, Guo R, et al. Targeting the circBMPR2/miR-553/USP4 axis as a potent therapeutic approach for breast cancer. Mol Ther Nucleic Acids. 2019;17:347–61.PubMedPubMedCentralCrossRef
98.
Qiu C, Liu Y, Mei Y, Zou M, Zhao Z, Ye M, et al. Ubiquitin-specific protease 4 promotes metastasis of hepatocellular carcinoma by increasing TGF-β signaling-induced epithelial–mesenchymal transition. Aging. 2018;10(10):2783–99.PubMedPubMedCentralCrossRef
99.
Li T, Yan B, Ma Y, Weng J, Yang S, Zhao N, et al. Ubiquitin-specific protease 4 promotes hepatocellular carcinoma progression via cyclophilin A stabilization and deubiquitination. Cell Death Dis. 2018;9(2):148.PubMedPubMedCentralCrossRef
100.
Heo MJ, Kim YM, Koo JH, Yang YM, An J, Lee SK, et al. microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression. Oncotarget. 2014;5(9):2792–806.PubMedPubMedCentralCrossRef
101.
Nguyen HH, Kim T, Nguyen T, Hahn MJ, Yun SI, Kim KK. A selective inhibitor of ubiquitin-specific protease 4 suppresses colorectal cancer progression by regulating β-catenin signaling. Cell Physiol Biochem. 2019;53(1):157–71.PubMedCrossRef
102.
Xing C, Lu XX, Guo PD, Shen T, Zhang S, He XS, et al. Ubiquitin-specific protease 4-mediated deubiquitination and stabilization of PRL-3 is required for potentiating colorectal oncogenesis. Cancer Res. 2016;76(1):83–95.PubMedCrossRef
103.
Zhou Y, Liang P, Ji W, Yu Z, Chen H, Jiang L. Ubiquitin-specific protease 4 promotes glioblastoma multiforme via activating ERK pathway. Onco Targets Ther. 2019;12:1825–39.PubMedPubMedCentralCrossRef
104.
Qin N, Han F, Li L, Ge Y, Lin W, Wang J, et al. Deubiquitinating enzyme 4 facilitates chemoresistance in glioblastoma by inhibiting P53 activity. Oncol Lett. 2019;17(1):958–64.PubMed
105.
Guo W, Ma J, Pei T, Zhao T, Guo S, Yi X, et al. Up-regulated deubiquitinase USP4 plays an oncogenic role in melanoma. J Cell Mol Med. 2018;22(5):2944–54.PubMedPubMedCentralCrossRef
106.
Hou X, Wang L, Zhang L, Pan X, Zhao W. Ubiquitin-specific protease 4 promotes TNF-α-induced apoptosis by deubiquitination of RIP1 in head and neck squamous cell carcinoma. FEBS Lett. 2013;587(4):311–6.PubMedCrossRef
107.
Yao R, Pu J, Fan R, Zhu W, Ding X, Shen X, et al. Ubiquitin-specific protease 4 improves the prognosis of the patients in esophageal cancer. Cancer Biomark. 2017;20(3):317–23.PubMedCrossRef
Metadata
Title
USP4 function and multifaceted roles in cancer: a possible and potential therapeutic target
Authors
Yizhi Wang
Li Zhou
Jun Lu
Bolun Jiang
Chengxi Liu
Junchao Guo
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01391-9

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Review

Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of the clinicopathological features and survival outcomes

Review

Early diagnosis of breast and ovarian cancers by body fluids circulating tumor-derived exosomes

Primary research

LBX2-AS1 up-regulated by NFIC boosts cell proliferation, migration and invasion in gastric cancer through targeting miR-491-5p/ZNF703

Primary research

The prognostic value of De Ritis (AST/ALT) ratio in patients after surgery for urothelial carcinoma: a systematic review and meta-analysis

Primary research

MiR-33a functions as a tumor suppressor in triple-negative breast cancer by targeting EZH2

Primary research

Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits